Sylvie Trottier
- Formation
-
MD
MSc
FRCPC
No active offer
All active job offers
- Principal area
- Infectious and immune diseases
- Address
- 2705, boulevard Laurier, RC-709
Québec (Quebec)
CANADA G1V 4G2 - Phone
- +1 418-525-4444, extension 42705
- Fax
- +1 418-654-2715
- sylvie.trottier@crchul.ulaval.ca
Recent publications (see all publication from this researcher)
Longtin Y, Trottier S, Brochu G, Paquet-Bolduc B, Garenc C, Loungnarath V, Beaulieu C, Goulet D, Longtin J. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
2013. 56: 67-73
Routy JP, Angel JB, Spaans JN, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N, Sekaly RP, Tremblay CL. Design and Implementation of a Randomized Crossover Study of Valproic Acid and Antiretroviral Therapy to Reduce the HIV Reservoir. HIV clinical trials,
2012. 13: 301-7
Routy J, Tremblay C, Angel J, Trottier B, Rouleau D, Baril J, Harris M, Trottier S, Singer J, Chomont N, Sekaly R, Boulassel M. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV medicine,
2012. 13: 291-6
Mbopi-Keou FX, Trottier S, Omar RF, Nkele NN, Fokoua S, Mbu ER, Domingo MC, Giguere JF, Piret J, Mwatha A, Masse B, Bergeron MG. A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women. Contraception,
2010. 81: 79-85
Cornut G, Gagnon S, Hankins C, Money D, Pourreaux K, Franco EL, Coutlee F, Canadian Women's HIV Study Group. Polymorphism of the capsid L1 gene of human papillomavirus types 31, 33, and 35. Journal of medical virology,
2010. 82: 1168-78
Mbopi-Keou FX, Trottier S, Omar RF, Nkele NN, Fokoua S, Mbu ER, Giguere JF, Domingo MC, Piret J, Tsague L, Zekeng L, Mwatha A, Masse B, Bergeron MG. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon. Contraception,
2009. 80: 484-92
Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN, INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. The Journal of infectious diseases,
2009. 200: 973-83
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H, MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. The New England journal of medicine,
2008. 359: 1429-41
SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Annals of internal medicine,
2008. 149: 289-99
Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E, MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. The New England journal of medicine,
2008. 359: 1442-55
